TOP TEN perturbations for 39314_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39314_at
Selected probe(set): 236126_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39314_at (236126_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.567751Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.5614872Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
precursor-B-ALL study 3 (MLL-rearranged) / T-ALL study 3
Relative Expression (log2-ratio):-2.4819508Number of Samples:5 / 29
Experimental | precursor-B-ALL study 3 (MLL-rearranged) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-2.4460468Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.4180622Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.3143559Number of Samples:2 / 13
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). |
renal cell carcinoma study 4 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.3110027Number of Samples:26 / 2
Experimental | renal cell carcinoma study 4 |
Tumor tissue samples from the kidney of patients with renal cell carcinoma (RCC). | |
Control | normal kidney tissue (fetal) |
Normal fetal kidney tissue samples. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.266511Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.2570229Number of Samples:3 / 3
Experimental | tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
hepatoblastoma study 1 (embryonal) / normal liver tissue
Relative Expression (log2-ratio):2.2394476Number of Samples:7 / 5
Experimental | hepatoblastoma study 1 (embryonal) |
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
Control | normal liver tissue |
Normal liver tissue samples. |